- Home
- HY vs AUTL Comparison
HY vs AUTL Comparison
Compare HY & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HY | AUTL |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.5M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HY | AUTL |
|---|---|---|
| Price | $32.60 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 141.4K | ★ 2.6M |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $3,913,600,000.00 | $51,128,000.00 |
| Revenue This Year | N/A | $669.49 |
| Revenue Next Year | N/A | $91.53 |
| P/E Ratio | $206.55 | ★ N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $26.41 | $1.11 |
| 52 Week High | $57.89 | $2.70 |
Technical Indicators
Market Signals| Indicator | HY | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 68.98 |
| Support Level | $28.83 | $1.77 |
| Resistance Level | $31.20 | $2.05 |
| Average True Range (ATR) | 1.20 | 0.12 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 77.73 | 91.84 |
Price Performance
Historical ComparisonAbout HY Hyster-Yale Materials Handling Inc.
Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.